Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 241 to 255 of 449 results for cardiovascular disease

  1. Balloon valvuloplasty for aortic valve stenosis in adults and children (HTG49)

    Evidence-based recommendations on balloon valvuloplasty for aortic valve stenosis in adults and children. This involves inflating a balloon inserted into the narrow valve to widen it so that blood can flow out more easily.

  2. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

  3. What is the efficacy and safety of remdesivir for people who have been vaccinated against COVID-19?

    severe COVID-19 disease, including (but not limited to): • aged 60 or over• immunosuppression• obesity• hypertension• chronic lung...

  4. Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)

    Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.

  5. Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.

  6. Upadacitinib for treating active ankylosing spondylitis (TA829)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults.

  7. Depression in adults with a chronic physical health problem: recognition and management (CG91)

    This guideline covers identifying, treating and managing depression in people aged 18 and over who also have a chronic physical health problem such as cancer, heart disease or diabetes. It aims to improve the care of people with a long-term physical health problem, which can cause or exacerbate depression. This has the potential to increase their quality of life and life expectancy.

  8. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  9. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  10. Mifamurtide for the treatment of osteosarcoma (TA235)

    Evidence-based recommendations on mifamurtide (Mepact) for treating osteosarcoma in people aged 2 to 30 years.

  11. VIDAvision for lung volume analysis in emphysema (MIB148)

    NICE has developed a medtech innovation briefing (MIB) on VIDAvision for lung volume analysis in emphysema .

  12. Use of hearing aids and incidence of dementia:- In adults with hearing loss, does the use of hearing aids reduce the incidence of dementia?

    susceptibility, environmental factors or age-related factors such as cardiovascular disease. Hearing loss may cause dementia either...

  13. Daratumumab in combination for treating newly diagnosed systemic amyloid light-chain amyloidosis (TA959)

    Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.

  14. Totally endoscopic robotically assisted coronary artery bypass grafting (HTG77)

    Evidence-based recommendations on totally endoscopic robotically assisted coronary artery bypass grafting (TECAB). This involves using small, remote-controlled robotic arms to carry out the grafting procedure.

  15. Cardiovascular disease prevention: cholesterol treatment target (secondary prevention) (IND268)

    This indicator has been updated and replaced by NICE indicator 278.